A First-in-Human Trial to Evaluate the Safety and Immunogenicity of a G Protein-Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18-45 Years of Age.

Vaccines (Basel) · 2023 · PMC10221330 · PMID 37243103

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

At day 60, the GMC value of the neutralization antibodies maintained an increasing trend and was up to 1683.6 IU/mL (95% CI: 904.1–3135.4 IU/mL) and 2499.6 IU/mL (95% CI: 1195–5228.3 IU/mL), respectively.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.